AzTrials
AzTrials

Illness Anxiety DisorderNCT03789084

Hybrid Trial of Brief Cognitive-Behavioral Therapy for Health Anxiety in Primary Care

A study testing Brief Cognitive-Behavioral Therapy for Health Anxiety and Referral to mental health provider in people with Illness Anxiety Disorder and Somatic Symptom Disorder, run by Dartmouth-Hitchcock Medical Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is a randomized controlled pilot trial using a hybrid type 1 effectiveness-implementation design to evaluate the feasibility, acceptability, and preliminary effectiveness of a brief cognitive-behavioral intervention delivered by medical assistants in a primary care setting. Read more about this study

Who is it for?
Ages 18 to 85 years
What is being tested?
Brief Cognitive-Behavioral Therapy for Health Anxiety and Referral to mental health provider
Could I receive a placebo?
No, everyone receives an active treatment
How many people
68 participants
Where
1 siteUnited States
Study dates
26 Mar 2019to 30 Oct 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age of 18 years to 85
  • Have a primary care provider at Dartmouth-Hitchcock Medical Center-General Internal Medicine, Dartmouth-Hitchcock Heater Road Clinic, or Dartmouth-Hitchcock Manchester
  • Primary care visit frequency of two standard deviations above the mean for patients in the individual's age by gender cohort
  • Elevated self-reported health anxiety (≥2 on Whiteley Index-7)
  • Diagnosis of illness anxiety disorder or somatic symptom disorder determined by Health Anxiety Interview

Who cannot join

  • Non-English speaking
  • Chronic medical illness necessitating an increased visit frequency confirmed through consultation with the patient's primary care provider
  • Active suicidal ideation
  • Unmanaged psychosis or unmanaged bipolar disorder

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire, 03756

Other trials in United States

About this study

Official title: A Hybrid Type 1 Trial Evaluating the Feasibility, Acceptability, Preliminary Effectiveness of Brief Cognitive-behavioral Therapy for Health Anxiety Delivered by Medical Assistants in Primary Care

This study is a randomized controlled pilot trial using a hybrid type 1 effectiveness-implementation design to evaluate the feasibility, acceptability, and preliminary effectiveness of a brief cognitive-behavioral intervention delivered by medical assistants in a primary care setting. The trial compares clinical outcomes of participants assigned to the intervention condition to those of participants assigned to a usual care condition. The clinical outcome is change on a self-report measure of health anxiety. Assessments occur at baseline, four weeks, and 12 weeks post-treatment. The study will also measure engagement with the intervention and assess feasibility and acceptability of the intervention in terms of fidelity of trained study therapists and ratings of the intervention by participants. The usual care condition consists of a referral to a mental health provider. The intervention is comprised of four sessions of individually administered cognitive-behavioral therapy addressing health anxiety. Treatment focuses on building motivation for change, psychoeducation about health anxiety, cognitive restructuring, and situational and interoceptive exposure. The study will recruit from three primary care clinics within the Dartmouth-Hitchcock Health system. The study will also assess facilitators and barriers to implementation using qualitative analyses of interview responses provided by the medical assistants delivering the intervention, primary care providers, and clinic administrators at the study sites.

Read the detailed description

Seventy-two health anxious patients with a diagnosis of Illness Anxiety Disorder or Somatic Symptom Disorder will be randomly assigned to either receive brief cognitive-behavioral therapy (CBT) administered by a medical assistant in the primary care practice where the patient receives their primary care services (intervention condition) or receive a referral to a mental health provider within the outpatient psychiatry clinic or another community provider of their choice (usual care condition). Randomization will be determined by a random number generation program at the point of enrollment. The randomization scheme will be stratified by primary care site to reduce site effects. The primary care sites from which patients will be recruited include the General Internal Medicine clinic at Dartmouth-Hitchcock Medical Center, Dartmouth-Hitchcock Heater Road clinic, and Dartmouth-Hitchcock Manchester. Recruitment will be evenly distributed across sites. The investigators will over-sample racial and ethnic minority patients at Dartmouth-Hitchcock Manchester due to the higher proportion of minority patients receiving services at that location.

The brief CBT intervention is a 4-session psychotherapy comprised of techniques guided by cognitive-behavioral theory and specifically derived from previously published materials. Each technique has support from prior randomized controlled trials demonstrating their efficacy for reducing symptoms of health anxiety and expert consensus. The techniques employed include motivational interviewing, psychoeducation, cognitive restructuring, and situational and interoceptive exposure. Each session of brief CBT is 45-minutes in duration and is delivered by a medical assistant who is principally located at the patient's primary care practice. All sessions are based on a manual developed by the Principal Investigator that includes essential elements to deliver at each session, scripts to guide delivery of the intervention, and homework assignments for the patient to complete between sessions and after completion of the final session. The Principal Investigator provides clinical supervision of the intervention over the course of the study.

The referral process employed in the usual care condition consists of an electronic referral made by the patient's primary care provider to a mental health provider within the Dartmouth-Hitchcock Health system, or a community provider outside of the system identified by the patient in consultation with the primary care provider. The nature of the intervention provided by the mental health provider is not prescribed or guided by the study protocol.

Examination of distributions of all variables using descriptive analyses will precede inferential statistical analysis. Transformations or recoding will be applied to normalize continuous data when necessary. The success of random assignment will be evaluated by comparing the two study groups on baseline characteristics using chi-square tests for categorical variables and t-tests for continuous covariates. If baseline variables are significantly different between groups and are significantly associated with the outcomes (e.g., medical comorbidity), the investigators will include them as covariates in the analytic models.

The primary outcome of change in health anxiety will be tested using a model that accommodates attrition and is appropriate for correlated data due to clustering (by 3 sites and 6 medical assistants) and repeated measures (baseline, 4 and 12 weeks) on the outcomes. Because there are only three assessment points, time will be treated as discrete and fitted to a covariance pattern model to compare average change between groups over time. Group (CBT vs usual care), time (baseline, 4 and 12 weeks), and the group by time interaction will be specified for the model. The treatment effect of intervention relative to control will be evaluated by testing significance of the group by time interaction term. An unstructured variance-covariance structure will be specified to account for the correlated nature of the data due to repeated measures.

The cluster size at site and provider levels are too small to be treated as random effects; therefore, the analysis will take clustering effects due to site and provider into account using small-sample robust estimate correction options implemented in the Statistical Analysis Software (SAS) generalized linear mixed models procedure (PROC GLIMMIX) procedure. GLIMMIX facilitates conducting mixed-effects and generalized estimating equation (GEE) modeling in the same procedure simultaneously.

The sample size was determined by a combination of recruitment feasibility, study therapist (medical assistant) availability, and power analysis. Given two groups, 3-assessment points, and sample size of 72 (36 per arm) with 15% attrition at 12 months (N = 58), and assuming cross-time correlation of 0.60, alpha of 0.05, and two-tailed tests, the study achieves 80% power to detect a minimum effect size of 0.69, between medium (0.50) and large (0.80) in Cohen's d-metric. If the analysis takes clustering effects due to site and providers into account by adjusting the sample size with an intraclass correlation (ICC) of 0.01, the study achieves 80% power to detect an effect size of 0.72. Statisticians recommend ICC between 0.01 and 0.02 in clinical studies with clustering; the investigators used ICC = 0.01 for this power calculation. A larger sample size is needed to detect effect sizes smaller than 0.69 and 0.72; however, sample size for pilot study should be based on pragmatics of recruitment and the necessities for examining feasibility, and not for purpose of inferential statistical tests.

The investigators will assess acceptability of the intervention and strategy using scores on a self-report measure of treatment acceptability using mean scores above a predetermined cut score denoting moderate acceptability across all participants. The investigators assess study therapist fidelity to the treatment by compiling standardized fidelity ratings for each session, nested within each provider, and converted to a percentage fidelity score.

Finally, the investigators will assess acceptability qualitatively using qualitative interviews with medical assistants, primary care providers, and clinic administrators. Interview data will be transcribed and entered verbatim into a qualitative data management software package for content analysis. Content analysis consists of reviewing the responses of interviewees to identify responses that are coded to correspond to Consolidated Framework for Implementation Research constructs. Coding will be conducted by two independent coders (the Principal Investigator and a research assistant) and overseen by a medical anthropologist.

Being tested
Brief Cognitive-Behavioral Therapy for Health Anxiety, Referral to mental health provider

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Brief Cognitive-Behavioral Therapy for Health AnxietyBehavioural

    4-session in-person 45-minute psychotherapy sessions focused on building motivation for change, psychoeducation, cognitive restructuring, and situational and interoceptive exposure to health-related fear stimuli.

  • Referral to mental health providerBehavioural

    Provider makes a referral to a mental health provider in the outpatient psychiatry clinic or a community provider of the participant's choice.

Study groups in NCT03789084
Study groupRoleWhat they receive
Cognitive-Behavioral TherapyExperimentalBrief Cognitive-Behavioral Therapy for Health Anxiety
Receives: Behavioral: Brief Cognitive-Behavioral Therapy for Health Anxiety
Referral to mental health providerOtherProvider makes referral to a mental health provider
Receives: Behavioral: Referral to mental health provider

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline in health anxiety, measured by the Short Health Anxiety Inventory

    The Short Health Anxiety Inventory is an 18-item measure of health anxiety in which respondents identify which statement applies best to them among four choices per item scored from 0 to 3 (e.g., "I do not worry about my health" = 0, "I spend most of my time worrying about my health" = 3). The scale range is 0 to 54. Higher scores correspond to increased health anxiety.

    Measured: Baseline, Post-treatment (4 weeks followup), 12-weeks Post-Treatment (12 weeks followup)

Secondary outcomes (2)
  1. Acceptability of the intervention, measured by the Treatment Evaluation Inventory-Short Form

    The Treatment Evaluation Inventory-Short Form is a 9-item measure of treatment acceptability (e.g., "I like the procedures used in this treatment") rated on a five-point Likert scale from "strongly disagree" to "strongly agree" and modified to focus on interventions administered to adults. The scale range is 9 to 45. Higher scores correspond to greater acceptability of the intervention.

    Measured: Post-treatment (4 weeks followup), 12-weeks Post-Treatment (12 weeks followup)

  2. Change in readiness for intervention, measured by the University of Rhode Island Change Assessment-Psychotherapy Version

    The University of Rhode Island Change Assessment-Psychotherapy Version is a 32-item measure of readiness for change. Items are rated on a five-point Likert scale from "strongly disagree" to "strongly agree" for each item (e.g., "I think I might be ready for some self-improvement."). The scale range is 32 to 160. Higher scores correspond to increased readiness for change.

    Measured: Baseline, Post-treatment (4 weeks followup), 12-weeks Post-Treatment (12 weeks followup)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Dec 2018
  2. Study start26 Mar 2019
  3. Primary completion1 Jul 2025
  4. Study completion30 Oct 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
68 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03789084
Sponsor's protocol ID
D19044
Other IDs
6K23MH116367-02
Status last verified
Jan 2026
First submitted
26 Dec 2018
Last updated
3 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Study results will be posted to ClinicalTrials.gov in a timely manner with the goal of posting the results as soon as possible following completion of primary analyses and not more than one year after completion of the final participant's participation in the trial. This corresponds to the third year of the career development award period for the hybrid trial covered in this study record. Deidentified individual participant data (IPD) will be available upon request from researchers with a sound research and analytic plan, including replication or inclusion in meta-analysis. IPD will be available immediately and indefinitely following primary outcome manuscript publication.

Publications

  • Brady RE, Hegel MT, Curran GM, Asmundson GJG, Xie H, Bruce ML. Evaluation of a brief psychosocial intervention for health anxiety delivered by medical assistants in primary care: Study protocol for a pilot hybrid trial. Contemp Clin Trials. 2021 Dec;111:106574. doi: 10.1016/j.cct.2021.106574. Epub 2021 Oct 7.

    PubMed 34628077
  • Brady RE, Braz AN. Challenging Interactions Between Patients With Severe Health Anxiety and the Healthcare System: A Qualitative Investigation. J Prim Care Community Health. 2023 Jan-Dec;14:21501319231214876. doi: 10.1177/21501319231214876.

    PubMed 38041442

Questions about this trial

What is this clinical trial studying?

A study testing Brief Cognitive-Behavioral Therapy for Health Anxiety and Referral to mental health provider in people with Illness Anxiety Disorder and Somatic Symptom Disorder, run by Dartmouth-Hitchcock Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline in health anxiety, measured by the Short Health Anxiety Inventory (time frame: Baseline, Post-treatment (4 weeks followup), 12-weeks Post-Treatment (12 weeks followup)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03789084, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2026; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in